CTRI/2021/03/032116Not yet recruiting未知
AN OPEN LABEL, SINGLE ARM CLINICAL STUDY ON THE EFFECTIVENESS OF VADAVANALA CHURNA IN HYPOTHYROIDISM
sri dharmasthala manjunatheshwara college of ayurveda and hospital0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1.THOSE WHO ARE NEWLY DETECTED OR ON ORAL THYROXINE THERAPHY
- •2. SUBJECTS OF EITHER GENDER
- •3. SUBJECTS AGED BETWEEN 18 - 60 YEARS
Exclusion Criteria
- •1.SUBJECTS WITH HISTORY OF THYROIDECTOMY, CONGENITAL HYPOTHYROIDISM, DRUG INDUCED, HYPOTHYROIDISM DUE TO INFILTRATIVE DISORDERS SACOIDOSIS, SYSTEMIC SCLEROSIS, HEMOCHROMATOSIS, PROGRESSIVE CASE OF MYXOEDEMA
- •2.KNOWN CASE OF RENAL, CARDIAC AND HEPATIC IMPAIRMENT
- •3.KNOWN CASE OF DIABETES MELLITUS AND MALIGNANT HYPERTENSION
- •4.PREGNANT AND LACTATING WOME
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Effect of Marmani Vati Lepa in IV cannula site swellingCTRI/2022/03/040773Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital
Recruiting
Phase 2
A Clinical Study on Vasa Khanda Kushmanda Avaleha (Ayurveda Medicine) in Acid Peptic Disease (Amlapitta)CTRI/2017/10/010032Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital Hassan30
Active, not recruiting
Phase 1
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early Stage Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002937-31-SEF. Hoffmann-La Roche Ltd1,225
Completed
Phase 3
An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosismultiple sclerosismsNL-OMON50626Roche Nederland B.V.24
Active, not recruiting
Phase 1
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early Stage Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002937-31-DEF. Hoffmann-La Roche Ltd1,225